Incyte ($INCY) announced an update on their ongoing clinical study. Study Overview Incyte’s new Phase 3 trial, titled “A Randomized, Double-Blind, ...

Bristol-Myers Squibb and BioNTech are launching ROSETTA HCC-206, an early-stage clinical trial in advanced or inoperable liver cancer (hepatocellular carcinoma). The study, officially titled “ROSETTA ...

The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...

Atezolizumab plus standard therapy was not associated with improved survival in advanced recurrent ovarian cancer.

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

CytomX has confirmed a Q1'26 readout for additional data from its trial of CX-2051 in colorectal cancer. Read why CTMX stock ...

Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...

WESTLAKE VILLAGE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and ...

High-risk advanced ovarian cancer patients showed marginal survival benefit with bevacizumab added to first-line chemotherapy. Patients without high-risk characteristics did not show significant ...

Credit: Biocon Biologics. Jobevne, a vascular endothelial growth factor inhibitor, was approved as a biosimilar to Avastin. Pharmacokinetic, safety, efficacy, and immunogenicity data showed Jobevne ...

Coherus BioSciences has launched a randomized Phase 2 study to evaluate the efficacy of casdozokitug (casdozo), an IL-27-antagonistic antibody, combined with toripalimab and bevacizumab for treating ...